ZUP1 and Miyoshi myopathy: DUB inhibitors are superior to proteasomal inhibitors in curing refractory tumors—e.g., b-AP15, a DUB inhibitor targeting USP14 and UCHL5, can overcome resistance to bortezomib, a 20S proteasome inhibitor, in MM [205,206,207].